Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Iq-ai Limited LSE:IQAI London Ordinary Share JE00BD4H0R42 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  +0.05p +4.17% 1.25p 2,022,576 16:35:06
Bid Price Offer Price High Price Low Price Open Price
1.10p 1.30p 1.30p 1.20p 1.20p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Retailers 0.16 -0.76 -0.82 0.8

Iq-ai (IQAI) Latest News (1)

More Iq-ai News
Iq-ai Takeover Rumours

Iq-ai (IQAI) Share Charts

1 Year Iq-ai Chart

1 Year Iq-ai Chart

1 Month Iq-ai Chart

1 Month Iq-ai Chart

Intraday Iq-ai Chart

Intraday Iq-ai Chart

Iq-ai (IQAI) Discussions and Chat

Iq-ai Forums and Chat

Date Time Title Posts
17/5/201917:38Imaging Quantification - Artificial Intelligence177

Add a New Thread

Iq-ai (IQAI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Iq-ai trades in real-time

Iq-ai (IQAI) Top Chat Posts

DateSubject
19/5/2019
09:20
Iq-ai Daily Update: Iq-ai Limited is listed in the General Retailers sector of the London Stock Exchange with ticker IQAI. The last closing price for Iq-ai was 1.20p.
Iq-ai Limited has a 4 week average price of 1.03p and a 12 week average price of 0.98p.
The 1 year high share price is 3.25p while the 1 year low share price is currently 0.98p.
There are currently 67,559,434 shares in issue and the average daily traded volume is 1,600,343 shares. The market capitalisation of Iq-ai Limited is £844,492.93.
16/5/2019
18:55
hedgehog 100: Hazl, I've noticed that you were an early fan of another AI stock, i.e. Blue Prism (PRSM), which has more than 20-bagged since it floated on AIM in 2016 at 78p, to its current share price of 1,848p (market cap. £1,415M.) Well done! From the Blue Prism (PRSM) thread - hazl 14 Apr '16 - 13:44 - 8 of 5494 "I like the look of these Schroders ...have a few it seems." hazl 14 Apr '16 - 19:20 - 13 of 5494 "Blue Prism, which made its debut on AIM last Friday, has joined the junior market with the ambition of creating a ‘big British’ software champion, according to chief executive Alastair Bathgate. That’s a bold statement of intent, but one that Bathgate reckons is eminently achievable following a listing that values the business at £48.5million and brought in £10million of new funds. The cash will be used to bankroll a major sales and marketing push of its world-leading robotic process automation. Ambitious: Blue Prism, which made its debut on AIM last Friday, has joined the junior market with the ambition of creating a ‘big British’ software champion, according to chief executive Alastair Bathgate.' Read more: http://www.thisismoney.co.uk/money/investing/article-3502829/Could-Blue-Prism-big-British-software-champion.html#ixzz45pI4mX18 Follow us: @MailOnline on Twitter | DailyMail on Facebook AN FT article is rather more sober about profitability but haven't found any reinforcement of that elsewhere yet. Interesting of the moment company that I believe may well succeed.IMO" http://uk.advfn.com/cmn/fbb/thread.php3?id=35298804 Earlier this year PRSM raised £100M. in a placing, which is a sign of investor enthusiasm for AI stocks: 24/01/2019 10:41 UK Regulatory (RNS & others) Blue Prism Group PLC Result of Placing " ... The Placing was conducted by way of an accelerated bookbuild. The Bookbuilding Process has now closed and the Company is pleased to announce that a total of 9,090,910 Placing Shares have been conditionally placed by Investec with certain existing and new institutional investors at an issue price of 1,100 pence per share (the "Placing Price"), raising approximately GBP100.0 million (before expenses) for the Company. ..." https://uk.advfn.com/stock-market/london/blue-prism-PRSM/share-news/Blue-Prism-Group-PLC-Result-of-Placing/79110782 The company is currently valued at twenty five its annual revenue of £55.2M., despite a pre-tax loss of £26M. Revenue growth is high though ... as indeed it should be at IQAI: 24/01/2019 07:00 UK Regulatory (RNS & others) Blue Prism Group PLC Full Year Results for the Year 31 October 2018 " ... Group revenue increased 125% ..." https://uk.advfn.com/stock-market/london/blue-prism-PRSM/share-news/Blue-Prism-Group-PLC-Full-Year-Results-for-the-Yea/79108559 30/04/2019 16:06 Alliance News IQ-AI Shares Jump As It Expects Sales To Double In 2019 30/04/2019 12:00 UK Regulatory (RNS & others) IQ-AI Limited Publication of Annual Report " ... We expect sales for the full year 2019 to more than double those for 2018. The future looks to be an exciting place for IQ-AI...." https://uk.advfn.com/stock-market/london/iq-ai-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846
15/5/2019
17:52
hedgehog 100: About 90 percent of drugs that reach clinical stage development never make it to FDA approval and commercialisation. Similarly, global energy consultant Wood MacKenzie has calculated the historical odds of a company making a commercial discovery from a frontier exploration well as less then one in 10. Fortunately for IQAI, the odds on gaining FDA approval for a medical device are the polar opposite of the above: more like a 90% chance of SUCCESS! And that's for medical devices in general. And in the case of IQAI's StoneChecker in particular, I think that we're now past the stage where it could fail. The main hurdles seem to have been crossed, and I think that we're now effectively at the stage of 'dotting i's and crossing t's'. That's why I think that the market is mispricing IQAI at the moment, at a paltry 1.2p. It's factoring in real fear of FDA failure, when in reality that isn't justified. Still, at least that means that the rise at approval should be even bigger than otherwise, and I fully expect IQAI to top the leader board when that happens. And even that should just be for starters, triggering a period of share price momentum upwards, and business advances. As regards the timing, I think that the FDA approval could now come at any moment. A few years ago, an eight-year study of FDA 510(k) review practices was published. The study looked at over 24,000 510(k) medical device submissions cleared between January 1, 2006 and December 31, 2013. One of the findings was that: "Almost two out of threel [sic] 510(k) applications are cleared within six months." HTTP://www.meddeviceonline.com/doc/how-long-does-the-fda-k-review-process-really-take-0001
12/5/2019
12:53
hedgehog 100: The 'gang of four' top management at IQAI is a veritable dream team of talent and ability: Trevor Brown, CEO of IQAI HTTP://www.flyingbrands.co.uk/ David Smith, Chief Operating Officer and CEO of the group's two operating businesses, StoneChecker Software and Imaging Biometrics Nick Stevens, CEO of Stone Checker Software Ltd HTTP://www.imagingbiometrics.com/what-we-offer/product-services/ib-stonechecker/ Michael Schmainda, CEO of Imaging Biometrics HTTP://www.imagingbiometrics.com/ And all four have invested significant sums into Flying Brands / IQAI within the last few/several months ... at a price of 2p per share or more: 11/09/2018 07:01 UK Regulatory (RNS & others) Flying Brands Limited Director/PDMR Shareholding "Flying Brands, the parent company of StoneChecker(R) and Imaging Biometrics(R) focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that David Smith, CEO to the Operating Subsidiaries of the Company, acquired 1,000,000 ordinary shares in the Company on 10 September 2018, representing 0.83% of the Company's issued share capital, at a price of 2.48 pence per share." http://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Director-PDMR-Shareholding/78229870 11/09/2018 09:00 UK Regulatory (RNS & others) Flying Brands Limited Director/PDMR Shareholding "Flying Brands, the parent company of StoneChecker(R) and Imaging Biometrics(R) focused on advanced and state of the art medical software and services, was notified on 10 September 2018 that Nick Stevens, CEO to Stone Checker Software Ltd, acquired 1,200,000 ordinary shares in the Company on 10 September 2018, representing 1% of the Company's issued share capital, at a price of 2.5 pence per share. Previously to this notification, Mr Stevens held 2,000,000 ordinary shares in the Company. Therefore Nick Steven's total shareholding represents 2.66% of the Company's issued share capital." http://uk.advfn.com/stock-market/london/flying-brand-FBDU/share-news/Flying-Brands-Limited-Director-PDMR-Shareholding/78231278 11/03/2019 07:00 UKREG IQ-AI Limited Issue of Convertible Loan Notes "IQ-AI is pleased to announce that the Company has issued GBP268,500 in nominal amount of 6% unsecured convertible loan notes 2024, convertible into 13,425,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 2 pence per share ("CLNs"). The funds raised as a result of the issue of the CLNs will be used to provide additional working capital for the Company. The funds raised enables the Company to fully execute its current business plan and shareholders should take comfort that the Company is now able to fully execute its current strategic objectives, following this, initially, non-dilutive fundraise. Trevor Brown, Chairman of the Company, has subscribed for GBP250,000 of the CLNs and Michael Schmainda, Chief Executive Officer of the Company's 100% owned subsidiary, Imaging Biometrics LLC, has subscribed for GBP18,500 of the CLNs. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Issue-of-Convertible-Loan-Notes/79437794 (IQAI's March 2019 fundraising conversion price of 2p was at a massive premium (56.86%) to the then IQAI share price (1.275p).) This sort of management 'cluster investment' into a share is a very bullish indicator, as it is a terrific vote of confidence in the company and its value.
10/5/2019
09:50
ged5: This was post 750 on the FDBK thread in reply to LR2:- Your figures for the accounts for 2017 and 2018 are correct. However the assets and liabilities could have several interpretations. I'll ask one of my daughters who is an accountant if she can shed any light on this. I see that in May 2016 FDBK agreed to sell its 50% equity interest in Stone Checker Software Ltd ('Stone Checker') to Free Association Books Limited, a company connected to one of Feedback's directors, Trevor Brown, for a cash consideration of £46,000 (the "Disposal"). Then in June 2017 8,000,000 ordinary shares of £0.01 each in the capital of the Company (the Consideration Shares) to the shareholders of Stone Checker Software Limited (the Target) in connection with the acquisition by the Company of the Target (the Acquisition). I've seen elsewhere the share price was 3p. I'm not sure who held the other 50% at this time. I must admit I'm not really interested in IQAI other than: 1. How much royalties FDBK receives on any sales of Stonechecker 2. What are the circumstances where TexRAD may terminate this agreement 3. Can Stonechecker receive FDA approval before Texrad 4. If Stonechecker receives FDA approval will it improve Texrad's chance of approval? Answer to No. 2:- TexRAD Limited is entitled to terminate the Patents Licence if: (1) it is determined by an expert that the Target has without legitimate reason failed to use diligent and reasonable efforts to develop and commercially exploit the TexRAD Plug-in; (2) the Target is in material breach of the Patents Licence and such breach is not remedied, if capable of remedy, within 30 days; or (3) if the Target becomes insolvent. The Patents Licence requires the Target to pay TexRAD Limited royalty payments. Accordingly, if the Target failed to meet these payments and failed to remedy this breach within 30 days, and this was determined to be a material breach of the Patents Licence, TexRAD would be entitled to terminate the Patents Licence. Accordingly, a key risk is that the Patents Licence is terminated. Http://www.flyingbrands.co.uk/wp-content/uploads/2017/05/Notice_To_Investors_Checker_Prospectus_17_05_2017.pdf
09/5/2019
19:00
hedgehog 100: 11/03/2019 07:00 UKREG IQ-AI Limited Issue of Convertible Loan Notes "IQ-AI is pleased to announce that the Company has issued GBP268,500 in nominal amount of 6% unsecured convertible loan notes 2024, convertible into 13,425,000 ordinary shares of 0.1p each in the Company ("Ordinary Shares") at a price of 2 pence per share ("CLNs"). The funds raised as a result of the issue of the CLNs will be used to provide additional working capital for the Company. The funds raised enables the Company to fully execute its current business plan and shareholders should take comfort that the Company is now able to fully execute its current strategic objectives, following this, initially, non-dilutive fundraise. Trevor Brown, Chairman of the Company, has subscribed for GBP250,000 of the CLNs and Michael Schmainda, Chief Executive Officer of the Company's 100% owned subsidiary, Imaging Biometrics LLC, has subscribed for GBP18,500 of the CLNs. ..." https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Issue-of-Convertible-Loan-Notes/79437794 IQAI's March 2019 fundraising had two major positives: 1. The fundraising conversion price of 2p was at a massive premium (56.86%) to the then IQAI share price (1.275p). 2. The investment of the two CEO's was akin to massive directors share buying, a huge vote of confidence in the company, especially at such a massive premium. This bodes well for the price of the next fundraising, and I'm expecting a period of very positive IQAI newsflow in the near future, driving the share price to much higher levels ahead of that fundraising. In fact, I would prefer a situation like this to one where a company doesn't need to raise funds for quite a while, and is happy to let the share price drift in the interim. It's interesting that someone has recently mentioned TERN here, because there are some similarities with TERN near its medium term low, though I consider IQAI to be better . I 'tipped' TERN on my RTO thread on 20.12.17 at 2.0p (see post 919), when its market cap. was £2.7M., and within six months it had more than 20-bagged, to over 40p. - THE REVERSE TAKEOVERS & SHELLS THREAD https://uk.advfn.com/cmn/fbb/thread.php3?id=31587598&from=919 TERN took advantage of its share price rise in 2018 to raise funds at far less dilution than otherwise - 08/05/2018 07:01 UK Regulatory (RNS & others) Tern PLC: Equity Fundraise Tern Plc (AIM:TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that it has raised GBP1,750,000 before expenses through an unconditional placing of 9,459,460 new ordinary shares of 0.02p each at a price of 18.50 pence per ordinary share (the "Placing") with a single institutional investor, utilising the existing share authorities granted at the 2018 AGM. ... https://uk.advfn.com/stock-market/london/tern-TERN/share-news/Tern-PLC-Equity-Fundraise/77363922 25/07/2018 07:01 UK Regulatory (RNS & others) Tern PLC: Equity Fundraise of c. GBP2.9m Tern Plc (AIM:TERN), the investment company specialising in the Internet of Things ("IoT"), is pleased to announce that it has raised approximately GBP2.9 million before expenses through an unconditional placing of 11,192,307 new ordinary shares of 0.02p each at a price of 26 pence per ordinary share (the "Placing"), utilising the existing share authorities granted at the 2018 AGM. ... https://uk.advfn.com/stock-market/london/tern-TERN/share-news/Tern-PLC-Equity-Fundraise-of-c-GBP2-9m/77926992
03/5/2019
13:34
hedgehog 100: The fact that FDA approval has taken so long shows how rigorous the process is, and also what a great achievement it will be. And one that will be monumental for IQAI's development, because America is such a vast and well-funded healthcare market, which is at the forefront of applying new technology. And IQAI appears to have a range of potential US reseller agreements lined up, which could be ready for signing once FDA marketing approval is received. - 08/02/2019 10:29 UKREG IQ-AI Limited Business Update “...Meanwhile IQ-AI continues to seek business development relationships that will expose its products to a broader audience worldwide. Several marketing and distribution alliances are under active consideration. These will be evaluated, and if appropriate, will be announced in the next few months....” https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Business-Update/79217612 30/04/2019 12:00 UKREG IQ-AI Limited Publication of Annual Report “... The Company will focus on four areas of revenue development in 2019: 1. Sales development of existing products During 2018, the Company sold or trialled software at many of the United States' most well-regarded hospitals and specialist clinics. IB Neuro remains the only 'biopsy confirmed' neuro perfusion software available on the market. Publicising this to all potential users is a key element of the Company's 2019 plans. We also intend to explore collaborative business relationships where our sales reach can be expanded by encouraging other companies' sales teams to promote our product for financial reward. This work is already underway with a series of resellers such as aycan Medical Systems, QMENTA, Blackford and Medimsight. ...” https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846 This bodes well for a period of very positive IQAI newsflow in the near future, driving the share price to much higher levels ahead of the next fundraising.
03/5/2019
13:05
hedgehog 100: 30/04/2019 12:00 UKREG IQ-AI Limited Publication of Annual Report “ ... The Company is in the final stages of securing FDA approval for the StoneChecker software product and we hope to announce marketing clearance shortly, which would give the Company an additional and important revenue stream in the US during the 2nd half of 2019. ...” https://uk.advfn.com/stock-market/london/iq-ai-ltd-IQAI/share-news/IQ-AI-Limited-Publication-of-Annual-Report/79794846 Hazl, The words "final stages" and "shortly" suggest that we are now very close. My sense is that it could now be imminent - perhaps even next week. But the important thing is that we've in effect had confirmation that it will be approved, and that there has been no major hitch. Approval should come as a major relief for all shareholders, and the share price should react accordingly. The share price only fell much below 2p because of the approval delay, so that should be the minimum to be expected after clearance.
09/12/2018
16:32
hulk2004: Half year report in September states fully funded for at least 12 months, so June/July/August they could run out of cash,a placing will come but I think more likely in April 2019 with FDA approval and other contracts announced so will be raised at higher price in theory.With 90 percent of AIM companies placings are never to far away so IQAI are no different, they might receive some management fees from the 2 companies for a period of time to keep them going but the pay off with this type of investment is when they dispose of the invested companies. I held Tern which in some ways are similar to IQAI and they went from 3p to 57p! Do not think that will happen here but if all goes to plan we could see a exit of 1 business with 12-18 months and I hope share price will be considerably higher than 2.8p!
Iq-ai share price data is direct from the London Stock Exchange
Your Recent History
LSE
IQAI
Iq-ai
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190519 12:45:41